e-learning resources

Discrepancies between anti-Intereukin5 (anti-IL5) starters from SHARP central registry and eligible patients in clinical trials

S. Principe (1) Amsterdam (The Netherlands) 2) Palermo, Netherlands), L. Richards (Amsterdam (The Netherlands), Netherlands), S. Hashimoto (Amsterdam (The Netherlands), Netherlands), J. Kroes (Leeuwarden, Netherlands), J. Van Bragt (Amsterdam (The Netherlands), Netherlands), S. Vijverberg (Amsterdam (The Netherlands), Netherlands), J. Sont (Leiden, Netherlands), N. Scichilone (Palermo, Netherlands), K. Bieksiene (Kaunas, Lithuania), A. Brinke (Leeuwarden, Netherlands), Z. Csoma (Budapest, Hungary), B. Dahlén (Stockholm, Sweden), B. Gemicioglu (Istanbul, Turkey), I. Grisle (Riga, Latvia), P. Kuna (Lódz, Poland), Z. Lazic (Kragujevac, Republic of Serbia), F. Mihaltan (Bucarest, Romania), S. Popovic-Grle (Zagreb , Croatia), S. Skgrat (Ljubljana, Slovenia), A. Maitland Van Der Zee (Amsterdam (The Netherlands), Netherlands)

Source: International Congress 2022 – Severe asthma: from phenotypes to exacerbations
Session: Severe asthma: from phenotypes to exacerbations
 Session type: Thematic Poster
 Number: 882

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
S. Principe (1) Amsterdam (The Netherlands) 2) Palermo, Netherlands), L. Richards (Amsterdam (The Netherlands), Netherlands), S. Hashimoto (Amsterdam (The Netherlands), Netherlands), J. Kroes (Leeuwarden, Netherlands), J. Van Bragt (Amsterdam (The Netherlands), Netherlands), S. Vijverberg (Amsterdam (The Netherlands), Netherlands), J. Sont (Leiden, Netherlands), N. Scichilone (Palermo, Netherlands), K. Bieksiene (Kaunas, Lithuania), A. Brinke (Leeuwarden, Netherlands), Z. Csoma (Budapest, Hungary), B. Dahlén (Stockholm, Sweden), B. Gemicioglu (Istanbul, Turkey), I. Grisle (Riga, Latvia), P. Kuna (Lódz, Poland), Z. Lazic (Kragujevac, Republic of Serbia), F. Mihaltan (Bucarest, Romania), S. Popovic-Grle (Zagreb , Croatia), S. Skgrat (Ljubljana, Slovenia), A. Maitland Van Der Zee (Amsterdam (The Netherlands), Netherlands). Discrepancies between anti-Intereukin5 (anti-IL5) starters from SHARP central registry and eligible patients in clinical trials. 882

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.